Prop-2-en-1-yl hexylcarbamate | 106533-30-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Prop-2-en-1-yl hexylcarbamate
• 英文别名: prop-2-enyl N-hexylcarbamate
• CAS: 106533-30-6
• 化学式: C₁₀H₁₉NO₂
• 分子量: 185.26
• InChiKey: NDMHCQBXLFZUIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  正己胺 、 碳酸二稀丙酯 在 esterase from Pyrobaculum calidifontis VA₁ 作用下， 以 aq. phosphate buffer 、 乙腈 为溶剂， 生成 Prop-2-en-1-yl hexylcarbamate
  参考文献：
  名称：

  10.1002/anie.202405152

  摘要：

  AbstractBiocatalysis provides an attractive approach to facilitate synthetic reactions in aqueous media. Motivated by the discovery of promiscuous aminolysis activity of esterases, we exploited the esterase from Pyrobaculum calidifontis VA1 (PestE) for the synthesis of carbamates from different aliphatic, aromatic, and arylaliphatic amines and a set of carbonates such as dimethyl‐, dibenzyl‐, or diallyl carbonate. Thus, aniline and benzylamine derivatives, aliphatic and even secondary amines could be efficiently converted into the corresponding benzyloxycarbonyl (Cbz)‐ or allyloxycarbonyl (Alloc)‐protected products in bulk water, with (isolated) yields of up to 99 %.

  DOI：

  10.1002/anie.202405152

文献信息

• Process for removing an amino protecting group
  申请人：NIPPON ZEON CO., LTD.

  公开号：EP0196454A1

  公开（公告）日：1986-10-08

  In a process for the production of an amino compound, the improvement wherein a protected amino compound containing an amino group protected with a 2- alkenyloxycarbonyl group is deprotected in contact with a compound of a platinum group metal as a catalyst in the presence of a formic acid compound selected from formic acid and salts thereof.

  在一种生产氨基化合物的工艺中，改进之处在于，在一种选自甲酸及其盐类的甲酸化合物存在下，与一种作为催化剂的铂族金属化合物接触，对一种含有用 2-烯氧羰基保护的氨基的受保护氨基化合物进行脱保护。
• [EN] OSW-1 ANALOGS AND CONJUGATES, AND USES THEREOF<br/>[FR] CONJUGUÉS ET ANALOGUES D'OSW-1, ET LEURS UTILISATIONS
  申请人：HARVARD COLLEGE

  公开号：WO2012159027A2

  公开（公告）日：2012-11-22

  Provided are a number of compounds structurally related to OSW-1, a natural compound that binds OSBPs. Also provided are pharmaceutical compositions comprising the OSW-1 analogs, as well as methods for use of these OSW-1 analogs, or pharmaceutically acceptable salts, enantiomers, or stereoisomers thereof, in the treatment of atherosclerosis, Alzheimer's disease, and cancer, including p21 -deficient cancer. Conjugates of OSW-1 analogs with monoclonal antibodies, including monoclonal antibodies targeted to cancer cells, are also provided. Also provided are pharmaceutical compositions comprising the conjugates, as well as methods for use of these conjugates, in the treatment of cancer, including p21 -deficient cancer.